Aprea Therapeutics, Inc.
APRE
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$0.70
FAIR PRICE
$1.12
MARGIN
$0.42
P/E Ratio
N/A
Div. Yield
N/A
ROE
-93.7%
Market Cap
$5M
Small-cap
COMING SOON
Get notified when APRE's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Oren Gilad
COUNTRY
US
HEADQUARTERS
Boston
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate APRE's fair price
Aprea Therapeutics, Inc.'s fair price of $1.12 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%). At the current market price of $0.70, APRE trades 60.0% below its calculated fair value.
DCF MODEL · 50%
Discounted cash flow analysis based on projected free cash flows, discounted at a rate reflecting APRE's risk profile.
RELATIVE · 30%
Comparing APRE's valuation multiples against Healthcare peers.
ANALYST · 20%
Aggregated analyst price targets for APRE, weighted by recency and analyst accuracy.
POWERED BY BULIOS
Get full analysis, financials, and AI insights for APRE.
Explore on BuliosFAQ
What is the fair price of APRE?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Aprea Therapeutics, Inc. is $1.12. At the current market price of $0.70, APRE trades 60.0% below its calculated fair value.
Is APRE overvalued or undervalued?+
Aprea Therapeutics, Inc. is currently undervalued based on our valuation model. The stock trades at $0.70, which is 60.0% below the fair price of $1.12.
How often is APRE's fair price updated?+
We update fair price calculations for APRE daily after market close. The current fair price of $1.12 incorporates the latest market data and sector multiples.
What factors affect APRE's fair price calculation?+
APRE's fair price of $1.12 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -93.7%.
Is APRE a good buy right now?+
At $0.70, APRE trades 60.0% below our fair value estimate of $1.12. The stock is currently undervalued. ROE stands at -93.7% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does APRE pay dividends?+
APRE does not currently pay a dividend.